FI960750A - Hermon kasvutekijän farmaseuttiset formulaatiot - Google Patents

Hermon kasvutekijän farmaseuttiset formulaatiot Download PDF

Info

Publication number
FI960750A
FI960750A FI960750A FI960750A FI960750A FI 960750 A FI960750 A FI 960750A FI 960750 A FI960750 A FI 960750A FI 960750 A FI960750 A FI 960750A FI 960750 A FI960750 A FI 960750A
Authority
FI
Finland
Prior art keywords
growth factor
nerve growth
pharmaceutical formulations
factor pharmaceutical
lyophilization
Prior art date
Application number
FI960750A
Other languages
English (en)
Swedish (sv)
Other versions
FI960750A0 (fi
FI113241B (fi
Inventor
Victoria M Knepp
Deborah M Lidgate
Richard Maskiewicz
Leo Gu
Original Assignee
Syntex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex Inc filed Critical Syntex Inc
Publication of FI960750A0 publication Critical patent/FI960750A0/fi
Publication of FI960750A publication Critical patent/FI960750A/fi
Application granted granted Critical
Publication of FI113241B publication Critical patent/FI113241B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/839—Nerves; brain

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FI960750A 1993-08-20 1996-02-19 Menetelmä hermon kasvutekijän stabiloimiseksi ja pitkäaikaiseksi varastoimiseksi FI113241B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10979893 1993-08-20
US08/109,798 US6277828B1 (en) 1993-08-20 1993-08-20 Pharmaceutical formulations of nerve growth factor
US9409245 1994-08-16
PCT/US1994/009245 WO1995005845A1 (en) 1993-08-20 1994-08-16 Pharmaceutical formulations of nerve growth factor

Publications (3)

Publication Number Publication Date
FI960750A0 FI960750A0 (fi) 1996-02-19
FI960750A true FI960750A (fi) 1996-02-20
FI113241B FI113241B (fi) 2004-03-31

Family

ID=22329623

Family Applications (1)

Application Number Title Priority Date Filing Date
FI960750A FI113241B (fi) 1993-08-20 1996-02-19 Menetelmä hermon kasvutekijän stabiloimiseksi ja pitkäaikaiseksi varastoimiseksi

Country Status (32)

Country Link
US (2) US6277828B1 (fi)
EP (1) EP0721343B1 (fi)
JP (2) JP4592830B2 (fi)
KR (1) KR100341193B1 (fi)
CN (1) CN1163265C (fi)
AT (1) ATE226085T1 (fi)
AU (1) AU677699B2 (fi)
BG (1) BG62951B1 (fi)
BR (1) BR9407278A (fi)
CA (1) CA2169834C (fi)
CZ (1) CZ292422B6 (fi)
DE (1) DE69431562T2 (fi)
DK (1) DK0721343T3 (fi)
ES (1) ES2181723T3 (fi)
FI (1) FI113241B (fi)
HK (1) HK1012990A1 (fi)
HU (1) HU228152B1 (fi)
IL (3) IL110725A (fi)
LT (1) LT4051B (fi)
LV (1) LV11279B (fi)
NO (1) NO317627B1 (fi)
NZ (1) NZ271873A (fi)
PL (1) PL176387B1 (fi)
PT (1) PT721343E (fi)
RO (1) RO114742B1 (fi)
RU (1) RU2126265C1 (fi)
SI (1) SI9420048B (fi)
SK (1) SK284064B6 (fi)
TW (1) TW427905B (fi)
UA (1) UA43348C2 (fi)
WO (1) WO1995005845A1 (fi)
ZA (1) ZA946333B (fi)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981485A (en) 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
EP0831883A1 (en) * 1995-05-12 1998-04-01 The Rockefeller University Treatment of alzheimer disease by modulation of synapsins
US6964947B1 (en) * 1995-11-07 2005-11-15 Genentech, Inc. Stabilizing formulation for NGF
US6090781A (en) * 1996-11-06 2000-07-18 Genentech, Inc. Stabilizing formulation for NGF
BR9611571B1 (pt) * 1995-11-07 2009-01-13 composiÇço farmacÊutica estÁvel, kit para administraÇço de ngf e produto medicinal.
AU3214597A (en) * 1996-05-29 1998-01-05 Universal Preservation Technologies, Inc. Long-term shelf preservation by vitrification
CN1059597C (zh) * 1996-08-08 2000-12-20 陈素兰 神经损伤修复制剂
JP4205172B2 (ja) * 1997-05-01 2009-01-07 プロテクション・アンリミテッド・インコーポレイテッド ワクチンアジュバントとしての神経成長因子
US6313089B1 (en) 1997-08-20 2001-11-06 Duke University Complexes of apolipoprotein E and ciliary neurotrophic factor (CNTF) and methods of use
JP2001518449A (ja) * 1997-09-30 2001-10-16 デューク・ユニバーシティー アポリポタンパク質ｅ／成長因子複合体およびその使用法
US6979442B1 (en) 1998-08-17 2005-12-27 Pfizer Inc. Stabilized protein compositions
EP1458408B1 (en) * 2001-12-21 2009-04-15 Novo Nordisk Health Care AG Liquid composition of factor vii polypeptides
KR20040065278A (ko) * 2001-12-21 2004-07-21 노보 노르디스크 에이/에스 변경된 인자 ⅶ 폴리펩티드의 액체 조성물
US20040009918A1 (en) * 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII
EP1517698B2 (en) 2002-06-21 2017-12-06 Novo Nordisk Health Care AG STABILISED SOLID COMPOSITIONS OF FACTOR VIIa POLYPEPTIDES
JP2006524195A (ja) * 2003-03-18 2006-10-26 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Ｖｉｉ因子ポリペプチドの液状水性医薬組成物
US7897734B2 (en) * 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
WO2004103398A1 (en) * 2003-05-23 2004-12-02 Novo Nordisk Health Care Ag Protein stabilization in solution
CN1318087C (zh) * 2003-06-06 2007-05-30 北京三诺佳邑生物技术有限责任公司 去白蛋白神经生长因子制剂
JP4658041B2 (ja) * 2003-06-25 2011-03-23 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Ｖｉｉ因子ポリペプチドの液体組成物
ATE446768T1 (de) * 2003-07-01 2009-11-15 Novo Nordisk Healthcare Ag Flüssige wässrige pharmazeutische zusammnesetzung von factor vii polypeptiden
EP1656158B1 (en) * 2003-08-14 2016-03-09 Novo Nordisk Health Care AG Liquid, aqueous pharmaceutical composition of factor vii polypeptides
EP2298287B1 (en) * 2003-12-19 2018-04-11 Novo Nordisk Health Care AG Stabilised compositions of factor VII polypeptides
US8017151B2 (en) * 2004-09-07 2011-09-13 Board Of Regents Of The University Of Nebraska By And Behalf Of The University Of Nebraska Medical Center Amphiphilic polymer-protein conjugates and methods of use thereof
US8168222B2 (en) 2004-09-07 2012-05-01 Board Of Regents Of The University Of Nebraska Amphiphilic polymer-protein conjugates and methods of use thereof
CN101500571A (zh) * 2006-08-14 2009-08-05 卫材R&D管理有限公司 稳定的冻干制剂
US8562506B2 (en) * 2006-11-08 2013-10-22 P-Mind Co., Ltd. Neurotrophic factor production promoting device
EP1958618A1 (de) * 2007-02-15 2008-08-20 Octapharma AG Verfahren zur Gefriertrocknung mit optimierter Rekonstitution von Biopolymeren
CN102196822A (zh) * 2008-09-26 2011-09-21 阿道恰公司 由多糖和hbp构成的复合物
CN102232932B (zh) * 2010-04-27 2013-06-05 重庆莱美药业股份有限公司 果胶-阿霉素轭合物的冻干制剂及制备方法
AU2012238643B2 (en) 2011-04-07 2017-04-13 Neovacs Method for treating IFNalpha related conditions
WO2013117729A1 (en) * 2012-02-08 2013-08-15 Institut National De La Recherche Agronomique Use of beta-nerve growth factor for inducing ovulation in mammals
DK3287140T3 (da) * 2015-04-21 2021-07-19 Beijing Staidson Medical Tech Co Ltd Nervevækstfaktorsammensætning og pulverinjektion
DK3287141T3 (da) * 2015-04-21 2021-10-11 Staidson Beijing Biopharmaceuticals Co Ltd Nervevækstfaktorsammensætning og injektionspulver
EP3287139B1 (en) * 2015-04-21 2021-08-11 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Nerve growth factor composition and injection powder
US9868828B2 (en) * 2015-06-23 2018-01-16 Amolifescience Co., Ltd. Defined three-dimensional microenvironment for stem cell
CA3018473A1 (en) 2016-03-25 2017-09-28 Astellas Pharma Inc. Pharmaceutical composition comprising pegylated fab' fragment of anti-human ngf antibody
EP3463308B1 (en) * 2016-06-01 2021-12-01 Servier IP UK Limited Formulations of polyalkylene oxide-asparaginase and methods of making and using the same
CN109260147B (zh) * 2018-10-15 2019-09-13 珠海亿胜生物制药有限公司 一种用于治疗或预防神经损伤的重组人碱性成纤维细胞生长因子注射剂
US11767504B2 (en) 2020-08-14 2023-09-26 Albcura Corporation Albumin compositions and methods of producing and using same
IL302317A (en) 2020-10-28 2023-06-01 Dompe Farm Spa Pharmaceutical packaging including polypropylene containers and aqueous formulations of NGF packed in them

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ222413A (en) 1986-11-05 1991-06-25 Ethicon Inc Compositions containing a polypeptide growth factor and a water-soluble cellulose polymer stabiliser
NZ226170A (en) * 1987-09-18 1990-07-26 Ethicon Inc Stable freeze-dried pharmaceutical composition containing epidermal growth factor
IT1219874B (it) * 1988-03-18 1990-05-24 Fidia Farmaceutici Utilizzazione del fattore di crescita nervoso umano e sue composizioni farmaceutiche
US5096885A (en) 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
JPH0418031A (ja) * 1989-02-16 1992-01-22 Hiroshi Saito 損傷治癒促進剤
JP3283288B2 (ja) * 1991-03-08 2002-05-20 電気化学工業株式会社 生理活性ペプチド製剤
JP2818834B2 (ja) * 1991-08-12 1998-10-30 大塚製薬株式会社 ＩＬ−１α安定化医薬製剤

Also Published As

Publication number Publication date
HUT74728A (en) 1997-02-28
DE69431562T2 (de) 2003-06-18
BG100371A (bg) 1996-12-31
CA2169834C (en) 2008-11-04
TW427905B (en) 2001-04-01
ES2181723T3 (es) 2003-03-01
AU7566894A (en) 1995-03-21
LV11279B (en) 1996-10-20
ZA946333B (en) 1996-02-19
BR9407278A (pt) 1996-10-01
NO960651L (no) 1996-02-19
CZ42496A3 (en) 1996-05-15
AU677699B2 (en) 1997-05-01
SI9420048B (sl) 2003-12-31
RU2126265C1 (ru) 1999-02-20
SK18396A3 (en) 1996-10-02
PL313084A1 (en) 1996-05-27
HU228152B1 (en) 2012-12-28
IL110725A0 (en) 1994-11-11
IL110725A (en) 2004-09-27
CN1133012A (zh) 1996-10-09
EP0721343A1 (en) 1996-07-17
IL124941A (en) 2006-12-10
US6277828B1 (en) 2001-08-21
JPH10508000A (ja) 1998-08-04
LT96011A (en) 1996-07-25
DE69431562D1 (de) 2002-11-21
SI9420048A (en) 1996-10-31
US7074763B2 (en) 2006-07-11
HK1012990A1 (en) 1999-08-13
PL176387B1 (pl) 1999-05-31
RO114742B1 (ro) 1999-07-30
IL124941A0 (en) 1999-01-26
LT4051B (en) 1996-10-25
NO317627B1 (no) 2004-11-29
JP4592830B2 (ja) 2010-12-08
UA43348C2 (uk) 2001-12-17
CZ292422B6 (cs) 2003-09-17
CA2169834A1 (en) 1995-03-02
WO1995005845A1 (en) 1995-03-02
DK0721343T3 (da) 2003-02-17
FI960750A0 (fi) 1996-02-19
EP0721343B1 (en) 2002-10-16
SK284064B6 (sk) 2004-09-08
US20010007662A1 (en) 2001-07-12
NZ271873A (en) 1996-10-28
FI113241B (fi) 2004-03-31
PT721343E (pt) 2003-01-31
ATE226085T1 (de) 2002-11-15
HU9600371D0 (en) 1996-04-29
LV11279A (lv) 1996-06-20
CN1163265C (zh) 2004-08-25
NO960651D0 (no) 1996-02-19
JP2007314572A (ja) 2007-12-06
BG62951B1 (bg) 2000-12-29
KR100341193B1 (ko) 2002-06-21

Similar Documents

Publication Publication Date Title
FI960750A0 (fi) Hermon kasvutekijän farmaseuttiset formulaatiot
NO971889L (no) Forbindelser og sammensetninger for levering av aktive midler
MX9203439A (es) Una citocina mamifera, il-11
IT1196484B (it) Vettore ad espressione e secrezione in lieviti,utile per la preparazione di proteine eterologhe
AU2789989A (en) Acylated uridine and cytidine and uses thereof
BG102708A (en) 4-aminopyrimidine derivatives, medicamentous preparations containing them, their application and method for their preparation
AU3065989A (en) Polypeptide compounds having growth hormone releasing activity
SE8504945D0 (sv) Pharmaceutical compositions containing anthracycline glycosides
IT8947794A0 (it) Proteine biologicamente attive, formulazioni che le contengono e metodo per prepararle ed applicarle
BR9611571A (pt) Composição farmacêutica estável composição farmacêutica kit para administração de ngf e método de aumento da estabilidade de ngf
ES2002083A6 (es) Un metodo para preparar derivados de piroglutamida
ATE341339T1 (de) Zusammensetzungen von rekombinanten papillomavirus vakzinen
AU2231688A (en) Stabilisation of therapeutically active proteins in a pharmaceutical composition
AU8769791A (en) Pharmaceutically active proteins comprising an active protein and an integrinaffinity sequence
DK0925064T3 (da) 5-Androsten-3-beta,17-alpha-diol som inhibitor for tumorvækst
UA5743C2 (uk) Препарат тканинних біологічно активних речовин, який має регенаторну дію, та спосіб його одержання
IT8921516A0 (it) Procedimento di microincapsulazione di microorganismi vivi e composizioni farmaceutiche stabili.
NO905375L (no) Fremg. og preparater for behandling av pattedyr-infeksjoner under anv. av medikamenter som omfatter hymenoptera venom, protein- eller polypepti-komponenter derav, eller analoger av slike protein- eller polypeptid-komponenter.
ITPS920005A0 (it) Procedimento di costruzione di pannelli in tamburato per mobili in genere, con cornici e scanalature fresate in profondita'
UA30787A (uk) Спосіб лікування хронічного персистуючого гепатиту
IT1246195B (it) Composizioni farmaceutiche contenenti antibiotici aminoglicosidici atte alla somministrazione topica

Legal Events

Date Code Title Description
MA Patent expired